GAMMA Investing LLC lifted its stake in Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 2,343.8% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 100,245 shares of the biopharmaceutical company's stock after acquiring an additional 96,143 shares during the period. GAMMA Investing LLC owned 0.08% of Dynavax Technologies worth $1,300,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors also recently made changes to their positions in the company. Rhumbline Advisers raised its holdings in shares of Dynavax Technologies by 4.7% in the 4th quarter. Rhumbline Advisers now owns 305,718 shares of the biopharmaceutical company's stock worth $3,904,000 after purchasing an additional 13,597 shares in the last quarter. Congress Asset Management Co. grew its position in Dynavax Technologies by 9.2% during the fourth quarter. Congress Asset Management Co. now owns 228,793 shares of the biopharmaceutical company's stock valued at $2,922,000 after purchasing an additional 19,271 shares in the last quarter. Palumbo Wealth Management LLC bought a new stake in Dynavax Technologies in the fourth quarter worth approximately $275,000. Principal Financial Group Inc. grew its position in Dynavax Technologies by 3.3% in the fourth quarter. Principal Financial Group Inc. now owns 596,590 shares of the biopharmaceutical company's stock worth $7,618,000 after acquiring an additional 18,863 shares in the last quarter. Finally, Sanctuary Advisors LLC grew its position in Dynavax Technologies by 6.3% in the fourth quarter. Sanctuary Advisors LLC now owns 18,836 shares of the biopharmaceutical company's stock worth $245,000 after acquiring an additional 1,109 shares in the last quarter. 96.96% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Several analysts have commented on DVAX shares. HC Wainwright reissued a "buy" rating and issued a $31.00 target price on shares of Dynavax Technologies in a research report on Friday, February 21st. Wall Street Zen downgraded shares of Dynavax Technologies from a "buy" rating to a "hold" rating in a report on Tuesday, May 6th. William Blair reaffirmed an "outperform" rating on shares of Dynavax Technologies in a report on Friday, February 21st. JMP Securities decreased their price objective on shares of Dynavax Technologies from $33.00 to $31.00 and set a "market outperform" rating for the company in a report on Wednesday, May 7th. Finally, The Goldman Sachs Group decreased their price objective on shares of Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating for the company in a report on Thursday, April 17th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $24.00.
Check Out Our Latest Analysis on Dynavax Technologies
Dynavax Technologies Price Performance
NASDAQ:DVAX opened at $10.27 on Monday. The stock has a market cap of $1.23 billion, a P/E ratio of 57.06 and a beta of 1.06. Dynavax Technologies Co. has a one year low of $9.22 and a one year high of $14.63. The company has a fifty day moving average price of $10.44 and a 200 day moving average price of $12.15. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34.
Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last released its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.14). The company had revenue of $68.16 million for the quarter, compared to analyst estimates of $70.01 million. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. Analysts anticipate that Dynavax Technologies Co. will post 0.32 earnings per share for the current year.
About Dynavax Technologies
(
Free Report)
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Dynavax Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dynavax Technologies wasn't on the list.
While Dynavax Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
